Neocell provides a PET reporter technology that makes cell and gene therapies visible to PET‑CT scans without triggering an immune response. This enables clinicians and researchers to non‑invasively monitor patients for early signs of treatment failure or toxicity, allowing timely intervention and reducing the cost and duration of unsuccessful trials.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and gene therapies are difficult to monitor in patients because existing imaging methods cannot directly visualize the therapeutic cells without triggering immune responses, leading to delayed detection of treatment failure or toxicity.
Solution
Neocell provides a PET reporter technology that can be incorporated into cell and gene therapy products, rendering them visible on standard PET‑CT scans while remaining immunologically inert. This enables clinicians to non‑invasively track the distribution, persistence, and activity of the therapies in real time. By correlating PET signal intensity with therapeutic efficacy, physicians can identify patients who are unlikely to achieve remission or who are at risk of treatment‑induced toxicity early in the course of therapy. The early insight supports timely intervention, such as rescuing ineffective treatments or administering prophylactic measures, thereby improving patient safety and reducing costly trial failures.
Target Audience
Primary customers are pharmaceutical and biotech companies developing cell or gene therapies, as well as clinical researchers and oncologists who need real‑time, non‑invasive monitoring of treatment efficacy and safety.
Features
- Immunologically silent PET reporter gene that can be stably expressed in a variety of cell and gene therapy vectors
- Compatibility with conventional PET‑CT scanners, requiring no specialized imaging equipment
- Quantitative imaging readouts that provide spatial and temporal metrics of cell engraftment and viability
- Integrated data pipeline for automated analysis and reporting of therapeutic response and toxicity risk
- Designed for use across multiple indications, including oncology, regenerative medicine, and pediatric applications where biopsies are impractical